<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887406</url>
  </required_header>
  <id_info>
    <org_study_id>104865</org_study_id>
    <nct_id>NCT00887406</nct_id>
  </id_info>
  <brief_title>Study of GSK961081 in Healthy Volunteer Subjects</brief_title>
  <official_title>A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetic Profile and Pharmacodynamics of Single and Repeat Inhaled Doses of GSK961081 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK961081 is a new long-acting bronchodilator being developed for the treatment of chronic
      obstructive pulmonary disease (COPD). This study is the first clinical study in humans. The
      purpose of this study is to determine the safety, tolerability, pharmacokinetics and
      pharmacodynamics of GSK961081 in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2005</start_date>
  <completion_date type="Actual">October 4, 2006</completion_date>
  <primary_completion_date type="Actual">October 4, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General safety and tolerability (adverse events, clinical laboratory safety tests, cardiac monitoring, vital signs (including postural changes in blood pressure), 12-lead ECG parameters including QTc(b) and QTc(f), blood glucose and serum potassium).</measure>
    <time_frame>Pre and post-dose on Days 1, 4 and 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maxiumum and weighted mean (over 0-8 hours post-dose) for systolic and diastolic blood pressure, heart rate, QTc(F), QTc(B), plasma glucose and serum potassium</measure>
    <time_frame>Days 1, 4 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>specific airway conductance (sGaW)</measure>
    <time_frame>pre and post-dose on Days 1, 4 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>forced expiratory volume in one second (FEV1)</measure>
    <time_frame>Pre and post-dose on Days 1, 4 and 7</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 100mcg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 300mcg or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 15mcg SD</intervention_name>
    <description>Single dose delivered via solution for nebulisation</description>
    <arm_group_label>Cohort 1, period 4</arm_group_label>
    <arm_group_label>Cohort 1, period 1</arm_group_label>
    <arm_group_label>Cohort 1, period 3</arm_group_label>
    <arm_group_label>Cohort 1, Period 2</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>GSK961081 200mcg SD</other_name>
    <other_name>GSK961081 50mcg SD</other_name>
    <other_name>GSK961081 300mcg SD</other_name>
    <other_name>GSK961081 100mcg SD</other_name>
    <other_name>GSK961081 3mcg SD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 3mcg SD</intervention_name>
    <description>single dose delivered via nebulsier</description>
    <arm_group_label>Cohort 1, period 4</arm_group_label>
    <arm_group_label>Cohort 1, period 1</arm_group_label>
    <arm_group_label>Cohort 1, period 3</arm_group_label>
    <arm_group_label>Cohort 1, Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 50mcg SD</intervention_name>
    <description>single dose delivered via solution for nebulisation</description>
    <arm_group_label>Cohort 1, period 4</arm_group_label>
    <arm_group_label>Cohort 1, period 1</arm_group_label>
    <arm_group_label>Cohort 1, period 3</arm_group_label>
    <arm_group_label>Cohort 1, Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SD</intervention_name>
    <description>single dose via nebuliser</description>
    <arm_group_label>Cohort 1, period 4</arm_group_label>
    <arm_group_label>Cohort 2, period 2</arm_group_label>
    <arm_group_label>Cohort 2, period 1</arm_group_label>
    <arm_group_label>Cohort 1, period 1</arm_group_label>
    <arm_group_label>Cohort 1, period 3</arm_group_label>
    <arm_group_label>Cohort 2, period 4</arm_group_label>
    <arm_group_label>Cohort 2, period 3</arm_group_label>
    <arm_group_label>Cohort 1, Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 100mcg SD</intervention_name>
    <description>single dose delivered via solution for nebulisation</description>
    <arm_group_label>Cohort 2, period 2</arm_group_label>
    <arm_group_label>Cohort 2, period 1</arm_group_label>
    <arm_group_label>Cohort 2, period 4</arm_group_label>
    <arm_group_label>Cohort 2, period 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 200mcg SD</intervention_name>
    <description>single dose via nebuliser</description>
    <arm_group_label>Cohort 2, period 2</arm_group_label>
    <arm_group_label>Cohort 2, period 1</arm_group_label>
    <arm_group_label>Cohort 2, period 4</arm_group_label>
    <arm_group_label>Cohort 2, period 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 300mcg SD</intervention_name>
    <description>single dose via nebuliser</description>
    <arm_group_label>Cohort 2, period 2</arm_group_label>
    <arm_group_label>Cohort 2, period 1</arm_group_label>
    <arm_group_label>Cohort 2, period 4</arm_group_label>
    <arm_group_label>Cohort 2, period 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 100mcg RD</intervention_name>
    <description>repeat dose via nebuliser</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>GSK961081 100mcg SD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 300mcg RD</intervention_name>
    <description>repeat dose vai nebuliser</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo RD</intervention_name>
    <description>repeat dose via nebuliser</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged between 18 and 50 years.

          -  Body mass index within the range 18.5-29.9 kilograms/meter2 (kg/m2).

          -  Forced Expiratory Volume in 1 second (FEV1) &lt;80% predicted and a FEV1/ Forced Vital
             Capacity (FVC) ratio &lt;0.7

          -  Response to Salbutamol defined as: an increase in sGAW of &gt;15% over pre-dose baseline
             within 2 h following administration of 400 mcg Salbutamol by MDI inhaler OR: a
             documented increase in sGAW of &gt;15% over pre-dose baseline within 2 h following
             administration of 400 mcg Salbutamol by MDI inhaler within 6 months of screening.

          -  Response to Ipratropium bromide defined as: an increase in sGaw of &gt;25% over pre-dose
             baseline within 2 h following 80 mcg Ipratropium bromide; OR: a documented increase in
             sGaw of &gt;25% over pre-dose baseline 2 h following administration of 80 mcg Ipratropium
             bromide within 6 months of screening.

          -  A signed and dated written informed consent is obtained for the subject

          -  The subject is able to understand and comply with the protocol requirements,
             instructions and protocol-stated restrictions.

          -  Subjects who are current non-smokers who have not used any tobacco products in the
             6-month period preceding the screening visit and have a pack history of &gt; or = 10 pack
             years.

        [number of pack years = (number of cigarettes per day/20) x number of years smoked]

        Exclusion Criteria:

          -  Any clinically relevant abnormality identified at the screening medical assessment
             (physical examination/medical history), clinical laboratory tests, or ECG (12-lead or
             Holter).

          -  A history of breathing problems (i.e. history of asthmatic symptoms). Screening lung
             function tests (FEV1, FVC and sGaw) will be performed to confirm normal lung function
             parameters.

          -  A mean QTc(B) and QTc(F) value at screening &gt;430msec, the 3 screening ECGs are not
             within 10% of the mean, a PR interval outside the range 120-210msec or an ECG that is
             not suitable for QT measurements (e.g. poorly defined termination of the T wave).

          -  A supine blood pressure that is persistently higher than 140/90 millimetres of mercury
             (mmHg) at screening.

          -  A supine mean heart rate outside the range 40-90 beats per minute (bpm) at screening.

          -  The subject has donated a unit of blood within the 90 days or intends to donate within
             90 days after completing the study.

          -  A history of claustrophobia such that they may not tolerate plethysmography
             measurements.

          -  The subject is currently taking regular (or course of) medication whether prescribed
             or not, including vitamins and herbal remedies such as St John's Wort.

          -  The subject has used prescription or non-prescription drugs, including vitamins,
             herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if
             the drug is a potential enzyme inducer) or 5 half-lives (which ever is longer) prior
             to the first dose of study medication, unless in the opinion of the Investigator and
             Sponsor the medication will not interfere with the study procedures or compromise
             subject safety.

          -  The subject has participated in a clinical study with another New Chemical Entity
             (NCE) within the past 112 days or a clinical study with any other drug during the
             previous 84 days.

          -  The subject is infected with the Hepatitis B, Hepatitis C, or HIV virus.

          -  The subject has a positive pre-study urine cotinine/ breath carbon monoxide test,
             urine drug/urine alcohol screen. A minimum list of drugs that will be screened for
             include Amphetamines, Barbituates, Cocaine, Opiates, Cannabinoids and Benzodiazepines.

          -  A history of regular alcohol consumption exceeding weekly intake of alcohol greater
             than 28 units, or an average daily intake of greater than 4 units.

          -  Are unable to use the Prodose AAD nebuliser device correctly.

          -  An unwillingness of subjects to abstain from sexual intercourse with pregnant or
             lactating women; or an unwillingness of the subject to use a condom/spermicide in
             addition to having their female partner use another form of contraception such as IUD,
             diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal
             implants or tubal ligation if the woman could become pregnant from the time of the
             first dose study medication until 90 days post-dose.

          -  The subject has a history of drug or other allergy, which, in the opinion of the
             responsible physician, contraindicates their participation.

          -  The subject has a history of hypersensitivity to Salbutamol or Ipratropium bromide,
             and for those subjects in cohorts III and IV, hypersensitivity to a beta-blocker.

          -  The subject has had a lower respiratory tract infection within 4 weeks of study start
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/104865?search=study&amp;search_terms=104865#rs</url>
    <description>Results for study 104865 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>first time in human study</keyword>
  <keyword>COPD</keyword>
  <keyword>long-acting bronchodilator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

